Coya therapeutics, inc. announces an agreement with dr. reddy's laboratories, ltd. to license its proposed biosimilar abatacept for the development and commercialization of coya 302 for the treatment of neurodegenerative diseases

Houston--(business wire)--coya therapeutics, inc. (nasdaq: coya) (“coya” or the “company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance treg function, including biologics and cell therapies, today announced a worldwide agreement with dr. reddy's laboratories limited. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy; hereafter referred to as “dr. reddy's”), a global pharmaceutical company.
RDY Ratings Summary
RDY Quant Ranking